RIM
CNCE

Rockbridge Investment Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Rockbridge Investment Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-300
Closed -$3K – 686
2020
Q2 		$3K Buy
+300
New +$2.88K ﹤0.01% 547

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LC
L1 Capital Melbourne VIC 3000, Australia $2.55B AUM 80.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rockbridge Investment Management's CNCE Position: Q3 2020 in Review

Rockbridge Investment Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2020, closing a stake of 300 shares — an estimated $3K sold.

Rockbridge Investment Management first reported a position in CNCE in Q2 2020 and held it in 1 quarter. The position peaked at $3K in Q2 2020. 92 funds tracked by Wall St. Rank hold CNCE as of Q3 2020.

  • Rockbridge Investment Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Rockbridge Investment Management sold 300 Concert Pharmaceuticals, Inc. shares in Q3 2020, an estimated $3K.
  • Rockbridge Investment Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2020 and held it in 1 quarter.
  • Rockbridge Investment Management's Concert Pharmaceuticals, Inc. position peaked at $3K in Q2 2020.
  • 92 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2020.

Based on Rockbridge Investment Management's 13F filing for Q3 2020, filed 3 Nov 2020.